Cargando…
Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666639/ https://www.ncbi.nlm.nih.gov/pubmed/36379917 http://dx.doi.org/10.1038/s41408-022-00750-1 |
| _version_ | 1784831553445036032 |
|---|---|
| author | Van Oekelen, Oliver Birrer, Nicole Wesson, William Galate, Vincent L. Cliff, Edward R. Scheffer Goodman, Aaron M. Abdallah, Al-Ola Chakraborty, Rajshekhar Prasad, Vinay Mohyuddin, Ghulam Rehman |
| author_facet | Van Oekelen, Oliver Birrer, Nicole Wesson, William Galate, Vincent L. Cliff, Edward R. Scheffer Goodman, Aaron M. Abdallah, Al-Ola Chakraborty, Rajshekhar Prasad, Vinay Mohyuddin, Ghulam Rehman |
| author_sort | Van Oekelen, Oliver |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9666639 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-96666392022-11-17 Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020 Van Oekelen, Oliver Birrer, Nicole Wesson, William Galate, Vincent L. Cliff, Edward R. Scheffer Goodman, Aaron M. Abdallah, Al-Ola Chakraborty, Rajshekhar Prasad, Vinay Mohyuddin, Ghulam Rehman Blood Cancer J Correspondence Nature Publishing Group UK 2022-11-15 /pmc/articles/PMC9666639/ /pubmed/36379917 http://dx.doi.org/10.1038/s41408-022-00750-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Van Oekelen, Oliver Birrer, Nicole Wesson, William Galate, Vincent L. Cliff, Edward R. Scheffer Goodman, Aaron M. Abdallah, Al-Ola Chakraborty, Rajshekhar Prasad, Vinay Mohyuddin, Ghulam Rehman Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020 |
| title | Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020 |
| title_full | Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020 |
| title_fullStr | Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020 |
| title_full_unstemmed | Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020 |
| title_short | Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020 |
| title_sort | characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015–2020 |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666639/ https://www.ncbi.nlm.nih.gov/pubmed/36379917 http://dx.doi.org/10.1038/s41408-022-00750-1 |
| work_keys_str_mv | AT vanoekelenoliver characteristicsofmeasurableresidualdiseaseassessmentinmyelomaareviewofclinicaltrialsfrom20152020 AT birrernicole characteristicsofmeasurableresidualdiseaseassessmentinmyelomaareviewofclinicaltrialsfrom20152020 AT wessonwilliam characteristicsofmeasurableresidualdiseaseassessmentinmyelomaareviewofclinicaltrialsfrom20152020 AT galatevincentl characteristicsofmeasurableresidualdiseaseassessmentinmyelomaareviewofclinicaltrialsfrom20152020 AT cliffedwardrscheffer characteristicsofmeasurableresidualdiseaseassessmentinmyelomaareviewofclinicaltrialsfrom20152020 AT goodmanaaronm characteristicsofmeasurableresidualdiseaseassessmentinmyelomaareviewofclinicaltrialsfrom20152020 AT abdallahalola characteristicsofmeasurableresidualdiseaseassessmentinmyelomaareviewofclinicaltrialsfrom20152020 AT chakrabortyrajshekhar characteristicsofmeasurableresidualdiseaseassessmentinmyelomaareviewofclinicaltrialsfrom20152020 AT prasadvinay characteristicsofmeasurableresidualdiseaseassessmentinmyelomaareviewofclinicaltrialsfrom20152020 AT mohyuddinghulamrehman characteristicsofmeasurableresidualdiseaseassessmentinmyelomaareviewofclinicaltrialsfrom20152020 |